Evotec SE (WBO:EVT) Research & Development : €50.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Evotec SE's Research & Development for the three months ended in Dec. 2023 was €20.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was €50.0 Mil.

Evotec SE Research & Development Historical Data

The historical data trend for Evotec SE's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Research & Development Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

58.43

63.95

72.20

76.64

68.53

Evotec SE Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Research & Development	Get a 7-Day Free Trial															18.48	21.32	12.38	17.50	20.16

Evotec SE Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €50.0 Mil.

Evotec SE (WBO:EVT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Evotec SE Research & Development Related Terms

Thank you for viewing the detailed overview of Evotec SE's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (WBO:EVT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines

From GuruFocus

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 10-20-2023

Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution

By PRNewswire PRNewswire • 01-15-2021

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 01-22-2024

Unveiling the Dividend Performance of EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND (EVT)

By GuruFocus Research • 09-21-2023